Drug · CHEMBL472
GLYBURIDE
7 sourcespipelines-2026-09-18-0.3.1
Cite this record
ConductScience Library. GLYBURIDE. Drugs and targets, record CHEMBL472. Release pipelines-2026-09-18-0.3.1, 18 Sept 2026. https://conductscience.org/library/drugs/CHEMBL472
On this page
Drug
Names and IDs as ChEMBL gives them, through Open Targets.
- Brand names
Amglidia, Calabren, Daonil, Diabeta, Diabetamide 2.5, Diabetamide 5, Euglucon, Gliken, Glyburide (micronized), Glyburide component of glucovance, Glynase, Lederglib, Libanil, Malix, Micronase, Semi-daonil
- ChEMBL
- Other names
AMGLIDIA, CALABREN, CIRARA, Cirara, DAONIL, DIABETA, DIABETAMIDE 2.5, DIABETAMIDE 5, EUGLUCON, GLIBENCLAMIDA, GLIBENCLAMIDE, GLIBENCLAMIDUM, GLIKEN, GLYBENCLAMIDE, GLYBURIDE (GLIBENCLAMIDE), GLYBURIDE (MICRONIZED), GLYBURIDE COMPONENT OF GLUCOVANCE, GLYBURIDE10238-21-8, GLYNASE, Glibenclamida, Glibenclamide, Glibenclamidum, Glybenclamide, HB 419, HB-419, LEDERGLIB, LIBANIL, MALIX, MICRONASE, NSC-759618, SEMI-DAONIL, U-26,45, U-26,452, U-26452
- ChEMBL
- Open Targets' highest stage
- Approval, for 2 of its 28 diseases, from ATC, DailyMed, EMA Human Drugs and FDA
- Open Targets
Targets2
The targets ChEMBL's mechanism records give for the drug, through Open Targets. A mechanism record says what the drug acts on, not how strongly.
| Target | Protein | Mechanism | Action | Gene in Genes |
|---|---|---|---|---|
| ABCC8 | Sulfonylurea receptor 1, Kir6.2 | Sulfonylurea receptor 1, Kir6.2 blocker | BLOCKER | https://conductscience.org/library/genes/6833 |
| KCNJ11 | Sulfonylurea receptor 1, Kir6.2 | Sulfonylurea receptor 1, Kir6.2 blocker | BLOCKER | https://conductscience.org/library/genes/3767 |
Source ChEMBL
Diseases28
The diseases Open Targets' clinical reports study the drug for, the most trial reports first. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
1 to 10 of 28Source Open Targets
See all 28 diseasesTrials98
Trials whose record names the drug by a name ChEMBL states, posted results first, then the largest. Open Targets read each trial's text to find its drugs.
| Trial | Title | Phase | Participants | Results first posted | Named as | Linked by | Source |
|---|---|---|---|---|---|---|---|
| NCT00313313 | A Study of Saxagliptin in Subjects With Type 2 Diabetes Who Have Inadequate Blood Sugar Control With Sulfonylureas | Phase 3 | 768 | 2009-09-25 | glyburide | Its name | ClinicalTrials.gov |
| NCT02864953 | Phase 3 Study to Evaluate the Efficacy and Safety of Intravenous BIIB093 (Glibenclamide) for Severe Cerebral Edema Following Large Hemispheric Infarction | Phase 3 | 535 | 2024-01-09 | glibenclamide | Its name | ClinicalTrials.gov |
| NCT00286468 | Study of Alogliptin Combined With Sulfonylurea in Subjects With Type 2 Diabetes Mellitus. | Phase 3 | 500 | 2011-08-25 | glyburide | Its name | ClinicalTrials.gov |
| NCT00393718 | Effect of Liraglutide on Blood Glucose Control in Subjects With Type 2 Diabetes | Phase 3 | 400 | 2010-03-12 | glibenclamide | Its name | ClinicalTrials.gov |
| NCT00744965 | Treatment of Mild Gestational Diabetes With Glyburide Versus Placebo | Phase 4 | 395 | 2020-03-12 | glyburide | Its name | ClinicalTrials.gov |
| NCT00965991 | Metformin Compared to Glyburide in Gestational Diabetes | 149 | 2023-12-21 | glyburide | Its name | ClinicalTrials.gov | |
| NCT00194896 | Preferred Treatment of Type 1.5 Diabetes | 64 | 2011-08-10 | glyburide | Its name | ClinicalTrials.gov | |
| NCT01822548 | Effect of Vildagliptin vs. Glibenclamide on Circulating Endothelial Progenitor Cell Number Type 2 Diabetes | Phase 3 | 64 | 2017-08-02 | glibenclamide | Its name | ClinicalTrials.gov |
| NCT00835991 | Glyburide/Metformin 5 mg/500 mg Film-Coated Tablets, Fed | Phase 1 | 60 | 2009-08-04 | glyburide | Its name | ClinicalTrials.gov |
| NCT00836472 | Glyburide/Metformin 5 mg/500 mg Film-Coated Tablets, Fasting | Phase 1 | 60 | 2009-08-04 | glyburide | Its name | ClinicalTrials.gov |
1 to 10 of 98
See all 98 trialsComparisons in its trials31
Comparisons Trial comparisons calculated in the trials whose record names the drug, most participants first. A comparison in one of its trials does not always compare the drug, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| BIIB093 vs Placebo: deaths from any cause | 103 of 259 | 97 of 259 | 518 | NCT02864953 | Trial comparisons |
| BIIB093 vs Placebo: serious adverse events | 199 of 259 | 177 of 259 | 518 | NCT02864953 | Trial comparisons |
| Liraglutide vs Glibenclamide: serious adverse events | 20 of 268 | 14 of 132 | 400 | NCT00393718 | Trial comparisons |
| Glyburide vs Placebo: Diagnosis of Pregnancy-induced Hypertension | 15 of 189 | 12 of 186 | 375 | NCT00744965 | Trial comparisons |
| Glyburide vs Placebo: 3rd or 4th Degree Perineal Laceration | 1 of 189 | 5 of 186 | 375 | NCT00744965 | Trial comparisons |
| Glyburide vs Placebo: Shoulder Dystocia | 0 of 189 | 1 of 186 | 375 | NCT00744965 | Trial comparisons |
| Glyburide vs Placebo: Macrosomia | 13 of 189 | 18 of 186 | 375 | NCT00744965 | Trial comparisons |
| Glyburide vs Placebo: Need for Insulin Treatment | 4 of 189 | 4 of 186 | 375 | NCT00744965 | Trial comparisons |
| Glyburide vs Placebo: Need for Insulin Therapy | 4 of 189 | 4 of 186 | 375 | NCT00744965 | Trial comparisons |
| Glyburide vs Placebo: Rate of Cesarean Delivery | 70 of 189 | 67 of 186 | 375 | NCT00744965 | Trial comparisons |
1 to 10 of 31
See all 31 comparisons in its trialsPapers from its trials81
The papers the trials whose record names the drug list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Tests in its trials0
The tests ConductCognition runs that the trials whose record names the drug name in their registered outcomes, as ScienceGraph matched them. ConductCognition's list names the tests it runs, not every test a trial used.
None in this release.
Data dates
The date of each source this release read.
Sources 7
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ConductCognition's list of its testsOur own data
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ConductCognition's list of its testsOur own data: ConductCognition's list of its tests, https://conductcognition.com
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this drug from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/drugs/v1/CHEMBL472
GET https://conductscience.org/api/drugs/v1/CHEMBL472/diseases?page=2